Xuening Duan

784 total citations
48 papers, 463 citations indexed

About

Xuening Duan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xuening Duan has authored 48 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 33 papers in Cancer Research and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xuening Duan's work include Breast Cancer Treatment Studies (30 papers), HER2/EGFR in Cancer Research (19 papers) and Breast Lesions and Carcinomas (9 papers). Xuening Duan is often cited by papers focused on Breast Cancer Treatment Studies (30 papers), HER2/EGFR in Cancer Research (19 papers) and Breast Lesions and Carcinomas (9 papers). Xuening Duan collaborates with scholars based in China, Taiwan and United Kingdom. Xuening Duan's co-authors include Jingming Ye, Ling Xu, Yinhua Liu, Yinhua Liu, Jianxin Zhao, Shuang Zhang, Tiantian Wang, Xingsong Tian, Luoyan Zhang and Zhen Zhang and has published in prestigious journals such as Scientific Reports, Medicine and Breast Cancer Research and Treatment.

In The Last Decade

Xuening Duan

47 papers receiving 457 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xuening Duan China 13 272 249 115 96 61 48 463
Erika Matos Slovenia 8 199 0.7× 210 0.8× 105 0.9× 57 0.6× 75 1.2× 27 409
Zhanlong Shen China 15 208 0.8× 234 0.9× 251 2.2× 80 0.8× 69 1.1× 30 537
Tomoyuki Aruga Japan 13 161 0.6× 230 0.9× 71 0.6× 91 0.9× 132 2.2× 59 403
Hiroko Nogi Japan 11 160 0.6× 155 0.6× 73 0.6× 69 0.7× 96 1.6× 41 380
Carolyn Cullinane Ireland 10 163 0.6× 188 0.8× 78 0.7× 83 0.9× 78 1.3× 29 366
Ingirídur Skírnisdóttir Sweden 16 107 0.4× 234 0.9× 176 1.5× 87 0.9× 77 1.3× 26 682
Amy Donahue United States 3 275 1.0× 163 0.7× 121 1.1× 73 0.8× 172 2.8× 5 367
Carey A. Eberle United States 7 206 0.8× 233 0.9× 101 0.9× 161 1.7× 92 1.5× 10 425
Lauren Nye United States 9 115 0.4× 270 1.1× 58 0.5× 42 0.4× 76 1.2× 37 369
C. Caroti Italy 9 158 0.6× 330 1.3× 138 1.2× 48 0.5× 72 1.2× 21 419

Countries citing papers authored by Xuening Duan

Since Specialization
Citations

This map shows the geographic impact of Xuening Duan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuening Duan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuening Duan more than expected).

Fields of papers citing papers by Xuening Duan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xuening Duan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuening Duan. The network helps show where Xuening Duan may publish in the future.

Co-authorship network of co-authors of Xuening Duan

This figure shows the co-authorship network connecting the top 25 collaborators of Xuening Duan. A scholar is included among the top collaborators of Xuening Duan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuening Duan. Xuening Duan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bao, Heling, Liwen Fang, Shu Cong, et al.. (2025). Female Breast Cancer Incidence and Association with Socioeconomic Status in a Population-Based Cohort — China, 2018–2024. China CDC Weekly. 7(10). 341–346.
2.
3.
Bao, Heling, Liyuan Liu, Shu Cong, et al.. (2023). Breast Cancer Awareness and Association with Frequency of Screening Among Women — China, 2020. China CDC Weekly. 5(15). 327–332. 7 indexed citations
4.
5.
Zhang, Zhuo, Hanxu Zhang, Chao Li, et al.. (2021). Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer. Thoracic Cancer. 12(24). 3396–3406. 18 indexed citations
6.
Wang, Fei, Xuening Duan, Rui Ling, & Zhigang Yu. (2021). Clinical practice guidelines for risk assessment to identify women at high risk of breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021. Chinese Medical Journal. 134(14). 1655–1657. 3 indexed citations
7.
Wang, Wei, Yinhua Liu, Hong Zhang, et al.. (2021). Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer. Gland Surgery. 10(12). 3211–3221. 16 indexed citations
8.
Zhang, Zhen, Luoyan Zhang, Zhigang Sun, et al.. (2020). Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer. Cancer Chemotherapy and Pharmacology. 86(6). 761–772. 55 indexed citations
9.
10.
Xu, Ling, et al.. (2017). Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy. Chinese Journal of Cancer Research. 29(4). 369–373. 2 indexed citations
11.
Zhou, Bin, Ling Xu, Jingming Ye, et al.. (2017). The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2- Enriched Subtype Breast Cancer, a Retrospective Analysis. Anticancer Research. 37(8). 4615–4621. 24 indexed citations
12.
13.
14.
Zhang, Hong, Ying Wang, Ling Xu, et al.. (2015). [Re-evaluation of HER2 status in 1 501 invasive breast cancers according to the 2013 American Society of Clinical Oncology/College of American Pathology guidelines].. PubMed. 44(1). 42–7. 2 indexed citations
15.
Liu, Shiwei, Xuening Duan, Ling Xu, et al.. (2015). Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 154(2). 239–249. 29 indexed citations
16.
17.
Zhang, Hong, Shuang Zhang, Qian Liu, et al.. (2015). [Analysis on clinical and pathological characteristics of 66 patients with stage IV breast cancer].. PubMed. 53(12). 935–40. 2 indexed citations
18.
Liu, Miao, Shu Wang, Shude Cui, et al.. (2015). The feasibility of the ACOSOG Z0011 Criteria to Chinese Breast Cancer Patients: A Multicenter Study. Scientific Reports. 5(1). 15241–15241. 15 indexed citations
19.
Zhang, Chi, Xuening Duan, Ling Xu, et al.. (2012). Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells. Breast Cancer Research and Treatment. 136(3). 739–748. 14 indexed citations
20.
Ye, Jingming, et al.. (2009). [Prospective study on the role of MRI and B ultrasonography in evaluating the tumor response to neoadjuvant chemotherapy in breast cancer].. PubMed. 47(5). 349–52. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erika Matos Breakdown of academic impact, for papers by Zhanlong Shen Breakdown of academic impact, for papers by Tomoyuki Aruga Breakdown of academic impact, for papers by Hiroko Nogi Breakdown of academic impact, for papers by Carolyn Cullinane Breakdown of academic impact, for papers by Ingirídur Skírnisdóttir Breakdown of academic impact, for papers by Amy Donahue Breakdown of academic impact, for papers by Carey A. Eberle Breakdown of academic impact, for papers by Lauren Nye Breakdown of academic impact, for papers by C. Caroti
Rankless by CCL
2026